Ozempic parent’s new weight-loss drug works better, but not quite good enough
New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss ...
Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 ...
The Print3h
Dr. Pratyaksha Bhardwaj’s Innovative Extracts Transform Weight Loss Landscape
Dr. Bhardwaj's pioneering approach has earned him widespread recognition, including the prestigious title of "World's Fastest ...
Devdiscourse1h
Novo Nordisk's CagriSema Trial Results Fall Short, Market Reacts
Novo Nordisk's obesity drug CagriSema failed to outperform Eli Lilly's Mounjaro in the latest trial, causing a dip in Novo's ...
Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results -- Update
Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate ...
Post Bulletin2h
Mayo Clinic Q&A: Weight loss and genetics
It seems like no matter what I do, I can't lose weight. Most of my family members struggle with their weight too. Do our ...
Eating Less of This Food Leads to Weight Loss in Just 8 Weeks
A new study breaks down exactly how to stop eating ultra-processed foods in eight weeks. Here's what it found and what ...
I’ve lost over 10 stone on Mounjaro – trolls call me ‘selfish’ and say it’ll ‘come back and bite’ me but I look great
A WOMAN has revealed that she lost over 10 stone after taking Mounjaro for seven months. Alexandra, who is from the UK but is ...
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...
Devdiscourse3h
Novo Nordisk's CagriSema: A Breakthrough in Obesity Treatment for Diabetics
Novo Nordisk's experimental drug, CagriSema, demonstrated a 15.7% weight reduction in obese individuals with type 2 diabetes over 68 weeks. Key findings from the phase III REDEFINE 2 trial highlight ...